Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This pilot study's primary aim is to compare rates of sustained opioid relapse, defined as
self-reported opioid use >50% (>15 of 30) of days during the first 30 days following release
from jail, among persons treated with XR-NTX pre-release vs. controls not receiving XR-NTX.
Phase:
Phase 3
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health
Collaborators:
Alkermes, Inc. New York City Department of Health and Mental Hygiene